TOZAWA Koiichi Nagoya City Univ.Medical School, Assistant, 医学部, 助手 (40264733)
KOJIMA Yukinori Nagoya City Univ.Medical School, Assistant, 医学部, 助手 (10260788)
HAYASHI Yutaro Nagoya City Univ.Medical School, Assistant, 医学部, 助手 (40238134)
|Budget Amount *help
¥2,200,000 (Direct Cost : ¥2,200,000)
Fiscal Year 1995 : ¥1,800,000 (Direct Cost : ¥1,800,000)
Fiscal Year 1994 : ¥400,000 (Direct Cost : ¥400,000)
In animal expriment, repeated instillation of saline can significantly increase tumor size in the urinary bladders of rats Initlated with BBN.This promotion effect partially allevlated by early stage BCG application in the present model. The results indicate that great care must be taken in choice of the vehicle for administration of chemotherapeutics for control of urinary bladder cancer.
Clinically, we compared effective and non-effective cases treated with intravesical instillation of BCG for prevention of recurrence of superficial bladder tumors. Fourteen bladder tumor patients under went transurethral resection, and H-ras, K-ras, or p53 genes were examined. LOH of p53 (7 cases) and RB (5 cases) was also assessad. There were 3 recurrences in the 2 year follow up period. One point mutation of p53,2 p53 LOH,and 1 RB LOH were observed. Only one of the recurrent cases had on LOH (RB). There was no apparent relationship between clinicopathological features of the original tumors, molecular biological changes and recurrence.
Using 23 specimens from superficial bladder cancer patients, we analyzed the mutation and the participation of p16 tumor suppressor gene. There was no mutation of p16 gene in these samples. But, the decrease of participation was found in 7 sample and suppression or participation in transcription level was suggested in bladder cancer.
Ar last, we examined immunohistochemical staining of three different antibodies of p53, PCNA,bcl-2 to 19 superficial bladder cancer specimens which were recurrent cases of BCG intravesical instillation treatment, and compared with non-recurrent cases. The result suggested that was some difference in PCNA and bcl-2 participation level between BCG sensitive and resistant tumor.